Foresite Capital — Pre-Seed & Seed VC Firm ($100K–$1.0M Checks)
Foresite Capital is a Pre-Seed, Seed venture capital firm based in San Francisco, CA investing in Healthcare, Deep Tech. The firm typically writes $100K–$1.0M checks and has 184 portfolio companies in our records.
- Check size
- $100K–$1.0M
- Portfolio
- 184 companies on record
- Partners
- 9 listed
- AUM
- $3.5B
- Stage
- Pre-Seed, Seed
- Sectors
- Healthcare, Deep Tech
- HQ
- San Francisco, CA
Last verified: 2026-05-22
Pre-Seed, Seed
$100K – $1.0M
$3.5B
184+ companies
9 partners
About Foresite Capital
Foresite Capital is a venture capital firm headquartered in San Francisco, CA. The firm focuses on transformative life sciences technologies, with a strong interest in biotech tools and platforms that enable next-generation research and development. Foresite Capital invests in the sectors of life sciences, biotech tools, healthcare, and deep tech.
The firm participates in pre-seed and seed stages with typical check sizes ranging from $100K to $1.0M. It has assets under management of $3.5B. Warm introductions are preferred when approaching the firm. The team includes Jim Tananbaum as CEO, Vijay Pande as General Partner focused on biotech, life sciences, and deep tech, along with Managing Directors Michael Rome and Hadi Tabbaa, and other members including Marvin Correa, Amelia Stoj, Luke Bagaason, Jonathan Robbins, Kevin Kelly, and Dennis Ryan.
Investment Thesis
Focuses on transformative life sciences technologies, with a strong interest in biotech tools and platforms that enable next-generation research and development.
How Foresite Capital invests
Foresite Capital is a vc firm based in San Francisco, CA. The firm invests at the Pre-Seed, Seed stages, with a focus on Healthcare, Deep Tech.
Foresite Capital typically writes checks of $100K–$1.0M per investment, backed by approximately $3.5B in assets under management.
Foresite Capital has backed 184 companies in our records, including Arzeda, Inscripta, XinThera.
Partners & Team
Industry Focus
Invests In
Recent Activity
Rumor has it: Life sciences investor Foresite Capital closing out third, $450M fund
Nov 2026 · MedCity News
How Venture Capital Backed America’s Biotech Engine | How America Makes Medicine Ep. 5
Aug 2026 · Foresite Capital
Foresite Welcomes New Venture Partner Jorge Reis-Filho
Aug 2026 · Foresite Capital
Investment Track Record
Foresite Capital has recorded investments in 184 portfolio companies. Notable investments include 10x Genomics, 89 Bio Inc., Abcuro, Abdera Therapeutics, Acceleron Pharma, Aclaris Therapeutics Inc., Adaptimmune Therapeutics PLC, Adaptive Biotechnologies Corporation, Adicet Bio Inc., Aduro Biotech, Aerie Pharmaceuticals Inc., Aetion, Affinivax, Aimmune Therapeutics Inc., and Akero Therapeutics. These span biotechnology and therapeutics as well as the firm's core sectors of life sciences, biotech tools, healthcare, and deep tech.
The firm has backed companies at various stages, including later rounds such as Abcuro's Series D, consistent with its focus on transformative technologies that advance research and development.
Portfolio Companies (184)
Other
Arzeda
Inscripta
XinThera
Health Verity
Eikon Therapeutics
10x Genomics
Theseus Pharmaceuticals
Pardes Biosciences
Xaira Therapeutics
Acceleron Pharma
- •Raising at Pre-Seed, Seed? You're squarely in their sweet spot.
- •Lead with your fit in Healthcare, Deep Tech — the sectors they actively back.
- •Size your ask to their typical $100K – $1.0M check.
- •warm intro preferred
- •Address your outreach to a specific partner, such as Jim Tananbaum, CEO.
- •A warm introduction beats a cold email. Get matched and request an intro.
Featured In
Browse More Investors
Fundraising resources
Frequently Asked Questions
See if Foresite Capital is a match for your startup
Upload your pitch deck to see how well you match with Foresite Capital and 10,000+ other investors.
Ask your AI assistant about this investor: connect InvestorMatch to Claude or ChatGPT
Is this your profile? Request a correction or removal